Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2014, Article ID 452853, 12 pages
http://dx.doi.org/10.1155/2014/452853
Review Article

The Role of Decay Accelerating Factor in Environmentally Induced and Idiopathic Systemic Autoimmune Disease

1Department of Ophthalmology, Duke University School of Medicine, Albert Eye Research Institute, Durham, NC 27710, USA
2Department of Surgery and Center for Investigations of Health and Education Disparities, University of California, San Diego, La Jolla, CA 92037, USA
3Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA

Received 10 October 2013; Accepted 19 November 2013; Published 27 January 2014

Academic Editor: Aristo Vojdani

Copyright © 2014 Christopher B. Toomey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. M. Hoffmann, “Inhibition of complement by a substance isolated from human erythrocytes—I. Extraction from human erythrocyte stromata,” Immunochemistry, vol. 6, no. 3, pp. 391–403, 1969. View at Google Scholar · View at Scopus
  2. A. Nicholson-Weller, D. B. Spicer, and K. F. Austen, “Deficiency of the complement regulatory protein, “decay-accelerating factor”, on membranes of granulocytes, monocytes, and platelets in paroxysmal nocturnal hemoglobinuria,” The New England Journal of Medicine, vol. 312, no. 17, pp. 1091–1097, 1985. View at Google Scholar · View at Scopus
  3. A. Nicholson-Weller, J. Burge, D. T. Fearon, P. F. Weller, and K. F. Austen, “Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system,” Journal of Immunology, vol. 129, no. 1, pp. 184–189, 1982. View at Google Scholar · View at Scopus
  4. D. M. Lublin and J. P. Atkinson, “Decay-accelerating factor: biochemistry, molecular biology, and function,” Annual Review of Immunology, vol. 7, pp. 35–58, 1989. View at Google Scholar · View at Scopus
  5. M. E. Medof, E. I. Walter, W. L. Roberts, R. Haas, and T. L. Rosenberry, “Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid,” Biochemistry, vol. 25, no. 22, pp. 6740–6747, 1986. View at Google Scholar · View at Scopus
  6. M. A. Davitz, M. G. Low, and V. Nussenzweig, “Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein,” Journal of Experimental Medicine, vol. 163, no. 5, pp. 1150–1161, 1986. View at Google Scholar · View at Scopus
  7. D. M. Lublin and K. E. Coyne, “Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage,” Journal of Experimental Medicine, vol. 174, no. 1, pp. 35–44, 1991. View at Google Scholar · View at Scopus
  8. F. Lin, Y. Fukuoka, A. Spicer et al., “Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies,” Immunology, vol. 104, no. 2, pp. 215–225, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Medof, E. I. Walter, J. L. Rutgers, D. M. Knowles, and V. Nussenzweig, “Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids,” Journal of Experimental Medicine, vol. 165, no. 3, pp. 848–864, 1987. View at Google Scholar · View at Scopus
  10. T. W. Post, M. A. Arce, M. K. Liszewski, E. S. Thompson, J. P. Atkinson, and D. M. Lublin, “Structure of the gene for human complement protein decay accelerating factor,” Journal of Immunology, vol. 144, no. 2, pp. 740–744, 1990. View at Google Scholar · View at Scopus
  11. A. Nicholson-Weller, J. P. March, and C. E. Rosen, “Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system,” Blood, vol. 65, no. 5, pp. 1237–1244, 1985. View at Google Scholar · View at Scopus
  12. D. J. Thomas and D. M. Lublin, “Identification of 5′-flanking regions affecting the expression of the human decay accelerating factor gene and their role in tissue-specific expression,” Journal of Immunology, vol. 150, no. 1, pp. 151–160, 1993. View at Google Scholar · View at Scopus
  13. D. M. Cauvi, G. Cauvi, and K. M. Pollard, “Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1,” Journal of Immunology, vol. 177, no. 6, pp. 3837–3847, 2006. View at Google Scholar · View at Scopus
  14. O. B. Spiller, O. Criado-Garcia, S. R. de Cordoba, and B. P. Morgan, “Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack,” Clinical and Experimental Immunology, vol. 121, no. 2, pp. 234–241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. E. T. Cocuzzi, D. Bardenstyein, A. Stavitsky, N. Sudarraj, and M. E. Medof, “Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-β and TNF-α,” Current Eye Research, vol. 23, no. 2, pp. 86–92, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. R. Ahmad, E. A. Lidington, R. Ohta et al., “Decay-accelerating factor induction by tumour necrosis factor-α, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition,” Immunology, vol. 110, no. 2, pp. 258–268, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. V. R. Holla, D. Wang, J. R. Brown, J. R. Mann, S. Katkuri, and R. N. DuBois, “Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer,” The Journal of Biological Chemistry, vol. 280, no. 1, pp. 476–483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. L. S. Davis, S. S. Patel, J. P. Atkinson, and P. E. Lipsky, “Decay-accelerating factor functions as a signal transducing molecule for human T cells,” Journal of Immunology, vol. 141, no. 7, pp. 2246–2252, 1988. View at Google Scholar · View at Scopus
  19. C. B. Toomey, D. M. Cauvi, W. Song, and K. M. Pollard, “Decay-accelerating factor 1 (Daf1) deficiency exacerbates xenobiotic-induced autoimmunity,” Immunology, vol. 131, no. 1, pp. 99–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Sogabe, M. Nangaku, Y. Ishibashi et al., “Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis,” Journal of Immunology, vol. 167, no. 5, pp. 2791–2797, 2001. View at Google Scholar · View at Scopus
  21. T. Miwa, M. A. Maldonado, L. Zhou et al., “Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice,” The American Journal of Pathology, vol. 161, no. 3, pp. 1077–1086, 2002. View at Google Scholar · View at Scopus
  22. J. Liu, F. Lin, M. G. Strainic et al., “IFN-γ and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production,” Journal of Immunology, vol. 180, no. 9, pp. 5882–5889, 2008. View at Google Scholar · View at Scopus
  23. F. Lin, H. J. Kaminski, B. M. Conti-Fine, W. Wang, C. Richmonds, and M. E. Medof, “Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection,” Journal of Clinical Investigation, vol. 110, no. 9, pp. 1269–1274, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Liu, T. Miwa, B. Hilliard et al., “The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo,” Journal of Experimental Medicine, vol. 201, no. 4, pp. 567–577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. D. D. Kim and W. C. Song, “Membrane complement regulatory proteins,” Clinical Immunology, vol. 118, no. 2-3, pp. 127–136, 2006. View at Publisher · View at Google Scholar
  26. M. Kolev, G. Le Friec, and C. Kemper, “The role of complement in CD4+ T cell homeostasis and effector functions,” Seminars in Immunology, vol. 25, no. 1, pp. 12–19, 2013. View at Publisher · View at Google Scholar
  27. P. Hillmen, J. M. Hows, and L. Luzzatto, “Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria,” The British Journal of Haematology, vol. 80, no. 3, pp. 399–405, 1992. View at Google Scholar · View at Scopus
  28. T. Masuda, Y. Yonemura, K. Fujimoto et al., “Establishment of a human T-cell line with deficient surface expression of glycosylphosphatidylinositol (GPI)-anchored proteins from a patient with paroxysmal nocturnal haemoglobinuria,” The British Journal of Haematology, vol. 87, no. 1, pp. 24–30, 1994. View at Google Scholar · View at Scopus
  29. J. Schubert, P. Uciechowski, P. Delany, H. J. Tischler, W. Kolanus, and R. E. Schmidt, “The PIG-anchoring defect in NK lymphocytes of PNH patients,” Blood, vol. 76, no. 6, pp. 1181–1187, 1990. View at Google Scholar · View at Scopus
  30. A. Hill, R. Kelly, and P. Hillmen, “Thrombosis in paroxysmal nocturnal hemoglobinuria,” Blood, vol. 121, no. 25, pp. 4985–4996, 2013. View at Publisher · View at Google Scholar
  31. M. E. Medof, A. Gottlieb, T. Kinoshita et al., “Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxymal nocturnal hemoglobinuria erythrocytes,” Journal of Clinical Investigation, vol. 80, no. 1, pp. 165–174, 1987. View at Google Scholar · View at Scopus
  32. M. E. Reid, G. Mallinson, R. B. Sim et al., “Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency),” Blood, vol. 78, no. 12, pp. 3291–3297, 1991. View at Google Scholar · View at Scopus
  33. M. J. Telen and A. M. Green, “The Inab phenotype: characterization of the membrane protein and complement regulatory defect,” Blood, vol. 74, no. 1, pp. 437–441, 1989. View at Google Scholar · View at Scopus
  34. G. L. Daniels, C. A. Green, G. Mallinson et al., “Decay-accelerating factor (CD55) deficiency phenotypes in Japanese,” Transfusion Medicine, vol. 8, no. 2, pp. 141–147, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. B. W. Boom, A. M. Mommaas, M. R. Daha, and B. J. Vermeer, “Decreased expression of decay-accelerating factor on endothelial cells of immune complex-mediated vasculitic skin lesions,” Journal of Dermatological Science, vol. 2, no. 4, pp. 308–315, 1991. View at Google Scholar · View at Scopus
  36. Y. Ichikawa, A. Masumoto, M. Yoshida et al., “Decay-accelerating factor (DAF, CD55)-negative T lymphocytes in the peripheral blood of Sjogren's syndrome patients,” Tokai Journal of Experimental and Clinical Medicine, vol. 21, no. 3, pp. 121–128, 1996. View at Google Scholar · View at Scopus
  37. G. T. Venneker, F. H. J. van den Hoogen, A. M. T. Boerbooms, J. D. Bos, and S. S. Asghar, “Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis: a possible mechanism of vascular damage,” Laboratory Investigation, vol. 70, no. 6, pp. 830–835, 1994. View at Google Scholar · View at Scopus
  38. G. T. Venneker, P. K. Das, B. Naafs, A. J. Tigges, J. D. Bos, and S. S. Asghar, “Morphoea lesions are associated with aberrant expression of membrane cofactor protein and decay accelerating factor in vascular endothelium,” The British Journal of Dermatology, vol. 131, no. 2, pp. 237–242, 1994. View at Google Scholar · View at Scopus
  39. G. T. Venneker, P. K. Das, M. M. H. M. Meinardi et al., “Glycosylphosphatidylinositol (GPI)-anchored membrane proteins are constitutively down-regulated in psoriatic skin,” Journal of Pathology, vol. 172, no. 2, pp. 189–197, 1994. View at Google Scholar · View at Scopus
  40. Y. Richaud-Patin, J. Piedras, E. Carrillo-Maravilla, X. López-Karpovitch, and L. Llorente, “CD8+ chronic lymphocytic leukemia: an extensive characterization of a bizarre hybrid neoplasia,” European Journal of Haematology, vol. 71, no. 3, pp. 224–230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. I. García-Valladares, Y. Atisha-Fregoso, Y. Richaud-Patin et al., “Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia,” Lupus, vol. 15, no. 9, pp. 600–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Francis, R. Rai, N. J. Sebire et al., “Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome,” Molecular Human Reproduction, vol. 12, no. 7, pp. 435–442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Zupanska, I. Bogdanik, J. Fabijanska-Mitek, and H. Pyl, “Autoimmune haemolytic anaemia with a paroxysmal nocturnal haemoglobinuria-like defect,” European Journal of Haematology, vol. 62, no. 5, pp. 346–349, 1999. View at Google Scholar · View at Scopus
  44. A. Ruiz-Argüelles and L. Llorente, “The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias,” Autoimmunity Reviews, vol. 6, no. 3, pp. 155–161, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Jones, I. Laffafian, A. M. Cooper, B. D. Williams, and B. P. Morgan, “Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis,” The British Journal of Rheumatology, vol. 33, no. 8, pp. 707–712, 1994. View at Google Scholar · View at Scopus
  46. M. Arora, A. Kumar, S. N. Das, and L. M. Srivastava, “Complement-regulatory protein expression and activation of complement cascade on erythrocytes from patients with rheumatoid arthritis (RA),” Clinical and Experimental Immunology, vol. 111, no. 1, pp. 102–106, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. Heckmann, H. Uwimpuhwe, R. Ballo, M. Kaur, V. B. Bajic, and S. Prince, “A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis,” Genes and Immunity, vol. 11, no. 1, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. M. J. G. J. van den Wijngaard, S. S. Asghar, A. C. L. M. Pijnenborg, A. J. Tigges, W. Westerhof, and P. K. Das, “Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo,” The British Journal of Dermatology, vol. 146, no. 1, pp. 80–87, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Agrawal, A. Sinha, T. Ahmad et al., “Maladaptation of critical cellular functions in asthma: bioinformatic analysis,” Physiological Genomics, vol. 40, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Kawai, S. Takeshita, Y. Imoto et al., “Associations between decay-accelerating factor polymorphisms and allergic respiratory diseases,” Clinical and Experimental Allergy, vol. 39, no. 10, pp. 1508–1514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Meletis, E. Terpos, M. Samarkos et al., “Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders,” Haematologia, vol. 31, no. 1, pp. 7–16, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Kaiafa, A. Papadopoulos, G. Ntaios et al., “Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome,” Annals of Hematology, vol. 87, no. 4, pp. 257–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Meletis, E. Terpos, M. Samarkos et al., “Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias,” International Journal of Hematology, vol. 75, no. 1, pp. 40–44, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Meletis, E. Terpos, M. Samarkos et al., “Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes,” Hematology Journal, vol. 2, no. 1, pp. 33–37, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. J. N. Waitumbi, M. O. Opollo, R. O. Muga, A. O. Misore, and J. A. Stoute, “Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia,” Blood, vol. 95, no. 4, pp. 1481–1486, 2000. View at Google Scholar · View at Scopus
  56. J. A. Stoute, A. O. Odindo, B. O. Owuor, E. K. Mibei, M. O. Opollo, and J. N. Waitumbi, “Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia,” Journal of Infectious Diseases, vol. 187, no. 3, pp. 522–525, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Waitumbi, B. Donvito, A. Kisserli, J. H. M. Cohen, and J. A. Stoute, “Age-related changes in red blood cell complement regulatory proteins and susceptibility to severe malaria,” Journal of Infectious Diseases, vol. 190, no. 6, pp. 1183–1191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. C. O. Odhiambo, W. Otieno, C. Adhiambo, M. M. Odera, and J. A. Stoute, “Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: implications for the development of severe anemia,” BMC Medicine, vol. 6, article 23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. R. C. Mahajan, K. Narain, and J. Mahanta, “Anaemia & expression levels of CD35, CD55 & CD59 on red blood cells in Plasmodium falciparum malaria patients from India,” Indian Journal of Medical Research, vol. 133, no. 6, pp. 662–664, 2011. View at Google Scholar · View at Scopus
  60. J. N. Jarvis, H. Taylor, P. M. Long, P. V. Gutta, T. Pousak, and N. Fine, “Diminished expression of cell-surface complement regulatory proteins in HIV-infected children and with HIV infection of peripheral blood mononuclear cells in vitro,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 9, no. 3, pp. 249–256, 1995. View at Google Scholar · View at Scopus
  61. E. Terpos, A. Sarantopoulos, A. Kouramba et al., “Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection,” Medical Science Monitor, vol. 14, no. 5, pp. CR276–CR280, 2008. View at Google Scholar · View at Scopus
  62. M. Yamaguchi, T. Machii, Y. Azenishi et al., “Detection of small populations of CD59-deficient erythrocytes in patients with aplastic anemia or myelodysplastic syndrome and normal individuals,” Blood Cells, Molecules, and Diseases, vol. 26, no. 3, pp. 247–254, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Wang, T. Chuhjo, H. Yamazaki et al., “Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis,” European Journal of Haematology, vol. 66, no. 3, pp. 200–205, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Hu, G. L. Mukhina, S. Piantadosi, J. P. Barber, R. J. Jones, and R. A. Brodsky, “PIG-A mutations in normal hematopoiesis,” Blood, vol. 105, no. 10, pp. 3848–3854, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. U. Oelschlaegel, I. Besson, C. Arnoulet et al., “A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes,” Clinical and Laboratory Haematology, vol. 23, no. 2, pp. 81–90, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. M. M. Lederman, S. F. Purvis, E. I. Walter, J. T. Carey, and M. E. Medof, “Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 11, pp. 4205–4209, 1989. View at Google Scholar · View at Scopus
  67. A. P. Alegretti, T. Mucenic, J. Merzoni, G. A. Faulhaber, L. M. Silla, and R. M. Xavier, “Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients,” Cellular Immunology, vol. 265, no. 2, pp. 127–132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. A. P. Alegretti, L. Schneider, A. K. Piccoli et al., “Diminished expression of complement regulatory proteins on peripheral blood cells from systemic lupus erythematosus patients,” Clinical and Developmental Immunology, vol. 2012, Article ID 725684, 9 pages, 2012. View at Publisher · View at Google Scholar
  69. K. B. Elkon and D. M. Santer, “Complement, interferon and lupus,” Current Opinion in Immunology, vol. 24, no. 6, pp. 665–670, 2012. View at Publisher · View at Google Scholar
  70. S. D. Webster, M. D. Galvan, E. Ferran, W. Garzon-Rodriguez, C. G. Glabe, and A. J. Tenner, “Antibody-mediated phagocytosis of the amyloid β-peptide in microglia is differentially modulated by C1q,” Journal of Immunology, vol. 166, no. 12, pp. 7496–7503, 2001. View at Google Scholar · View at Scopus
  71. D. M. Santer, A. E. Wiedeman, T. H. Teal, P. Ghosh, and K. B. Elkon, “Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene induction by lupus immune complexes,” Journal of Immunology, vol. 188, no. 2, pp. 902–915, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. M. J. Walport, “Complement (second of two parts),” The New England Journal of Medicine, vol. 344, no. 15, pp. 1140–1144, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Richaud-Patin, B. Pérez-Romano, E. Carrillo-Maravilla et al., “Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus,” Immunology Letters, vol. 88, no. 2, pp. 95–99, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. V. Pavlov, H. Raedler, S. Yuan et al., “Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection,” Journal of Immunology, vol. 181, no. 7, pp. 4580–4589, 2008. View at Google Scholar · View at Scopus
  75. P. S. Heeger, P. N. Lalli, F. Lin et al., “Decay-accelerating factor modulates induction of T cell immunity,” Journal of Experimental Medicine, vol. 201, no. 10, pp. 1523–1530, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Miwa, M. A. Maldonado, L. Zhou et al., “Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/Ipr mice via both complement-dependent and -independent mechanisms,” The American Journal of Pathology, vol. 170, no. 4, pp. 1258–1266, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Vas and M. Monestier, “Immunology of mercury,” Annals of the New York Academy of Sciences, vol. 1143, pp. 240–267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. M. A. Lynes, A. P. Fontenot, D. A. Lawrence, A. J. Rosenspire, and K. M. Pollard, “Gene expression influences on metal immunomodulation,” Toxicology and Applied Pharmacology, vol. 210, no. 1-2, pp. 9–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Hultman, U. Johansson, S. J. Turley, U. Lindh, S. Eneström, and K. M. Pollard, “Adverse immunological effects and autoimmunity induced by dental amalgam and alloy in mice,” FASEB Journal, vol. 8, no. 14, pp. 1183–1190, 1994. View at Google Scholar · View at Scopus
  80. D. H. Kono, D. Balomenos, D. L. Pearson et al., “The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-γ and not Th1/Th2 imbalance,” Journal of Immunology, vol. 161, no. 1, pp. 234–240, 1998. View at Google Scholar · View at Scopus
  81. K. Warfvinge, H. Hansson, and P. Hultman, “Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice: dose-response studies,” Toxicology and Applied Pharmacology, vol. 132, no. 2, pp. 299–309, 1995. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Hultman, S. J. Turley, S. Eneström, U. Lindh, and K. M. Pollard, “Murine genotype influences the specificity, magnitude and persistence of murine mercury-induced autoimmunity,” Journal of Autoimmunity, vol. 9, no. 2, pp. 139–149, 1996. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Hultman and J. B. Nielsen, “The effect of dose, gender, and non-H-2 genes in murine mercury-induced autoimmunity,” Journal of Autoimmunity, vol. 17, no. 1, pp. 27–37, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Schiraldi and M. Monestier, “How can a chemical element elicit complex immunopathology? Lessons from mercury-induced autoimmunity,” Trends in Immunology, vol. 30, no. 10, pp. 502–509, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Hultman, L. J. Bell, S. Enestrom, and K. M. Pollard, “Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains,” Clinical Immunology and Immunopathology, vol. 65, no. 2, pp. 98–109, 1992. View at Publisher · View at Google Scholar · View at Scopus
  86. K. M. Pollard, P. Hultman, and D. H. Kono, “Immunology and genetics of induced systemic autoimmunity,” Autoimmunity Reviews, vol. 4, no. 5, pp. 282–288, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. L. M. Bagenstose, R. Class, P. Salgame, and M. Monestier, “B7-1 and B7-2 co-stimulatory molecules are required for mercury-induced autoimmunity,” Clinical and Experimental Immunology, vol. 127, no. 1, pp. 12–19, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. K. M. Pollard, M. Arnush, P. Hultman, and D. H. Kono, “Costimulation requirements of induced murine systemic autoimmune disease,” Journal of Immunology, vol. 173, no. 9, pp. 5880–5887, 2004. View at Google Scholar · View at Scopus
  89. L. M. Bagenstose, P. Salgame, and M. Monestier, “Mercury-induced autoimmunity in the absence of IL-4,” Clinical and Experimental Immunology, vol. 114, no. 1, pp. 9–12, 1998. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Havarinasab, K. M. Pollard, and P. Hultman, “Gold- and silver-induced murine autoimmunity—requirement for cytokines and CD28 in murine heavy metal-induced autoimmunity,” Clinical and Experimental Immunology, vol. 155, no. 3, pp. 567–576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Vas, J. Mattner, S. Richardson et al., “Regulatory roles for NKT cell ligands in environmentally induced autoimmunity,” Journal of Immunology, vol. 181, no. 10, pp. 6779–6788, 2008. View at Google Scholar · View at Scopus
  92. K. M. Pollard and D. H. Kono, “Requirements for innate immune pathways in environmentally induced autoimmunity,” BMC Medicine, vol. 11, article 100, 2013. View at Google Scholar
  93. K. M. Pollard, D. L. Pearson, P. Hultman, T. N. Deane, U. Lindh, and D. H. Kono, “Xenobiotic acceleration of idiopathic systematic autoimmunity in lupus-prone BXSB mice,” Environmental Health Perspectives, vol. 109, no. 1, pp. 27–33, 2001. View at Google Scholar · View at Scopus
  94. K. M. Pollard, D. L. Pearson, P. Hultman, B. Hildebrandt, and D. H. Kono, “Lupus-prone mice as models to study xenobiotic-induced acceleration of systemic autoimmunity,” Environmental Health Perspectives, vol. 107, no. 5, pp. 729–735, 1999. View at Google Scholar · View at Scopus
  95. M. Abedi-Valugerdi, H. Hu, and G. Möller, “Mercury-induced renal immune complex deposits in young (NZB × NZW)F1 mice: characterization of antibodies/autoantibodies,” Clinical and Experimental Immunology, vol. 110, no. 1, pp. 86–91, 1997. View at Google Scholar · View at Scopus
  96. F. W. Miller, L. Alfredsson, K. H. Costenbader et al., “Epidemiology of environmental exposures and human autoimmune diseases: findings from a national institute of environmental health sciences expert panel workshop,” Journal of Autoimmunity, vol. 39, no. 4, pp. 253–258, 2012. View at Publisher · View at Google Scholar
  97. S. C. L. Farhat, C. A. Silva, M. A. M. Orione, L. M. A. Campos, A. M. E. Sallum, and A. L. F. Braga, “Air pollution in autoimmune rheumatic diseases: a review,” Autoimmunity Reviews, vol. 11, no. 1, pp. 14–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. I. A. Silva, J. F. Nyland, A. Gorman et al., “Mercury exposure, malaria, and serum antinuclear/antinucleolar antibodies in amazon populations in Brazil: a cross-sectional study,” Environmental Health, vol. 3, article 11, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. G. S. Cooper, C. G. Parks, E. L. Treadwell, E. W. St Clair, G. S. Gilkeson, and M. A. Dooley, “Occupational risk factors for the development of systemic lupus erythematosus,” Journal of Rheumatology, vol. 31, no. 10, pp. 1928–1933, 2004. View at Google Scholar · View at Scopus
  100. A. M. Abréu Vélez, G. Warfvinge, W. L. Herrera et al., “Detection of mercury and other undetermined materials in skin biopsies of endemic pemphigus foliaceus,” The American Journal of Dermatopathology, vol. 25, no. 5, pp. 384–391, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. R. M. Gardner, J. F. Nyland, I. A. Silva, A. Maria Ventura, J. M. de Souza, and E. K. Silbergeld, “Mercury exposure, serum antinuclear/antinucleolar antibodies, and serum cytokine levels in mining populations in Amazonian Brazil: a cross-sectional study,” Environmental Research, vol. 110, no. 4, pp. 345–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. S. J. Li, S. H. Zhang, H. P. Chen et al., “Mercury-induced membranous nephropathy: clinical and pathological features,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 3, pp. 439–444, 2010. View at Publisher · View at Google Scholar
  103. D. M. Cauvi, G. Cauvi, and K. M. Pollard, “Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease,” Arthritis and Rheumatism, vol. 56, no. 6, pp. 1934–1944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. D. M. Cauvi, C. B. Toomey, and K. M. Pollard, “Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease,” Immunology, vol. 135, no. 4, pp. 333–343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Sekine, C. M. Reilly, I. D. Molano et al., “Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice,” Journal of Immunology, vol. 166, no. 10, pp. 6444–6451, 2001. View at Google Scholar · View at Scopus
  106. R. J. M. Abbott, I. Spendlove, P. Roversi et al., “Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55,” The Journal of Biological Chemistry, vol. 282, no. 30, pp. 22023–22032, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. E. N. Kop, M. Matmati, W. Pouwels, G. Leclercq, P. P. Tak, and J. Hamann, “Differential expression of CD97 on human lymphocyte subsets and limited effect of CD97 antibodies on allogeneic T-cell stimulation,” Immunology Letters, vol. 123, no. 2, pp. 160–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. J. Hamann, C. van Zeventer, A. Bijl, C. Molenaar, K. Tesselaar, and R. A. W. van Lier, “Molecular cloning and characterization of mouse CD97,” International Immunology, vol. 12, no. 4, pp. 439–448, 2000. View at Google Scholar · View at Scopus
  109. M. Capasso, L. G. Durrant, M. Stacey, S. Gordon, J. Ramage, and I. Spendlove, “Costimulation via CD55 on human CD4+ T cells mediated by CD97,” Journal of Immunology, vol. 177, no. 2, pp. 1070–1077, 2006. View at Google Scholar · View at Scopus
  110. R. V. Sutavani, R. G. Bradley, J. M. Ramage, A. M. Jackson, L. G. Durrant, and I. Spendlove, “CD55 costimulation induces differentiation of a discrete T regulatory type 1 cell population with a stable phenotype,” Journal of Immunology, vol. 191, no. 12, pp. 5895–5903, 2013. View at Publisher · View at Google Scholar
  111. C. Kemper, A. C. Chan, J. M. Green, K. A. Brett, K. M. Murphy, and J. P. Atkinson, “Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype,” Nature, vol. 421, no. 6921, pp. 388–392, 2003. View at Publisher · View at Google Scholar · View at Scopus
  112. C. M. Karsten and J. Köhl, “The complement receptor CD46 tips the scales in T H 1 self-control,” Nature Immunology, vol. 11, no. 9, pp. 775–777, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. S. M. Truscott, G. Abate, J. D. Price, C. Kemper, J. P. Atkinson, and D. F. Hoft, “CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses,” Infection and Immunity, vol. 78, no. 12, pp. 5295–5306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Hsieh and J. L. Bautista, “Sliding set-points of immune responses for therapy of autoimmunity,” Journal of Experimental Medicine, vol. 207, no. 9, pp. 1819–1823, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. K. M. Pollard, P. Hultman, C. B. Toomey et al., “Definition of IFN-γ-related pathways critical for chemically-induced systemic autoimmunity,” Journal of Autoimmunity, vol. 39, no. 4, pp. 323–331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. H. Y. Wu, F. J. Quintana, A. P. da Cunha et al., “In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling,” PLoS ONE, vol. 6, no. 8, Article ID e23618, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Pot, L. Apetoh, A. Awasthi, and V. K. Kuchroo, “Molecular pathways in the induction of interleukin-27-driven regulatory type 1 cells,” Journal of Interferon and Cytokine Research, vol. 30, no. 6, pp. 381–388, 2010. View at Google Scholar · View at Scopus
  118. H. Y. Wu, F. J. Quintana, and H. L. Weiner, “Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+CD25-LAP+ regulatory T Cell and is associated with down-regulation of IL-17+CD4+ICOS +CXCR5+ follicular helper T cells,” Journal of Immunology, vol. 181, no. 9, pp. 6038–6050, 2008. View at Google Scholar · View at Scopus
  119. A. Viola, S. Schroeder, Y. Sakakibara, and A. Lanzavecchia, “T lymphocyte costimulation mediated by reorganization of membrane microdomains,” Science, vol. 283, no. 5402, pp. 680–682, 1999. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Legembre, S. Daburon, P. Moreau, J. F. Moreau, and J. L. Taupin, “Cutting edge: modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes,” Journal of Immunology, vol. 176, no. 2, pp. 716–720, 2006. View at Google Scholar · View at Scopus
  121. M. P. Longhi, B. Sivasankar, N. Omidvar, B. P. Morgan, and A. Gallimore, “Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner,” Journal of Immunology, vol. 175, no. 11, pp. 7098–7102, 2005. View at Google Scholar · View at Scopus